Expression of gp200-MR6 in Bladder Carcinomas
Author Information
Author(s): MF Tungekar, KC Gatter, MA Ritter
Primary Institution: United Medical and Dental Schools of Guy's and St Thomas' Hospitals Trust
Hypothesis
The study investigates the expression of gp200-MR6 in transitional cell carcinomas of the bladder and its implications for interleukin 4 in tumor therapy.
Conclusion
All bladder carcinomas expressed gp200-MR6, suggesting its potential role in tumor therapy and homeostasis of urothelium.
Supporting Evidence
- All 28 bladder carcinomas expressed gp200-MR6.
- gp200-MR6 was also expressed in all control non-neoplastic urothelia.
- Expression of mutant p53 protein and epidermal growth factor receptor was detected in 14/28 and 20/28 cases respectively.
- Proliferation indices ranged from 5% to 95% among the tumors.
Takeaway
The study found that a specific molecule, gp200-MR6, is present in all bladder tumors, which could help in treating these cancers.
Methodology
The study used immunohistochemical staining on 28 surgically excised bladder tumors and 12 control specimens of non-neoplastic urothelium.
Limitations
The study does not address the functional implications of gp200-MR6 expression in tumor behavior.
Participant Demographics
The study involved 28 patients with transitional cell carcinomas of various grades and stages.
Want to read the original?
Access the complete publication on the publisher's website